⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25492620 | 1.00 | — | — | |
| SCHEMBL21687065 | 0.93 | — | — | |
| SCHEMBL24098480 | 0.91 | FGF1 (0.30) | — | |
| SCHEMBL10020490 | 0.91 | FGF1 (0.30) | — | |
| SCHEMBL15149899 | 0.91 | FGF1 (0.30) | — | |
| SCHEMBL18098021 | 0.88 | — | — | |
| SCHEMBL23710655 | 0.84 | — | — | |
| SCHEMBL21473728 | 0.84 | — | — | |
| SCHEMBL12416889 | 0.83 | — | — | |
| SCHEMBL19543083 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230287424-A1 | RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION | BANK OF AMERICA, N.A. | 2023-09-14 | — | — | US | disclosed |
| US-20230193284-A1 | TRANSMEMBRANE SERINE PROTEASE 2 (TMPRSS2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-06-22 | — | — | US | disclosed |
| US-20230032974-A1 | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-02-02 | — | — | US | disclosed |
| US-20220380762-A1 | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2022-12-01 | — | — | US | disclosed |
| US-20220290145-A1 | Modified RNA Agents with Reduced Off-Target Effect | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | US | disclosed |